Sharda Cropchem Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Fertilizers & Agrochemicals | Market Cap: ₹6.9K Cr
The company maintains FY27 revenue growth guidance of 10%-15%. The company expects sustained revenue growth of 10%-15% for FY27.
From Sharda Cropchem's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹765
Market Cap
₹6.9K Cr
P/E Ratio
11.0
Revenue Rank
Margin Rank
How does Sharda Cropchem rank in Fertilizers & Agrochemicals?
Compare Sharda Cropchem against every Fertilizers & Agrochemicals company this quarter on revenue, margins and earnings-call signals.
Sharda Cropchem — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.1K Cr, net profit ₹319 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →The company maintains FY27 revenue growth guidance of 10%-15%.
- →Volume growth for the year is expected around 10%, with recovery anticipated particularly in Europe after a slower Q1.
- →Europe is expected to rebound strongly in the next three quarters, recovering from weather-related volume decline.
- →NAFTA and LATAM regions have shown strong volume growth in Q1 and are expected to maintain momentum.
- →Future growth is expected from both volume increases and new product additions with higher realizations.
- →The company anticipates sustained investment in product registrations to support long-term growth.
- →Overall, all three key markets (Europe, NAFTA, LATAM) are expected to contribute positively to growth going forward.
📈 Profitability & Margins
Rank 3- →The company expects sustained revenue growth of 10%-15% for FY27.
- →Gross margins are anticipated to remain in the range of 35% to 37%.
- →EBITDA margin guidance is maintained at 18%-20%.
- →Operating performance shows strength with PBT (excluding FOREX impact) growth of 16% YoY.
- →Europe volumes are expected to recover strongly over the next three quarters, helping overall growth.
- →NAFTA and LATAM regions continue to show strong growth momentum.
- →New product additions along with volume growth are expected to drive future earnings growth.
- →Management remains cautiously optimistic given external factors like weather and currency volatility but is focused on long-term growth through sustained investments.
🏗️ Capital Expenditure Plans
Yes- →Sharda Cropchem continues to invest significantly in intangible CAPEX, mainly product registrations, with annual investment around Rs. 450-500 crores.
- →The high CAPEX of Rs. 273 crores in Q1 FY27 included some unusual data compensation spend but the company has not revised its full-year CAPEX guidance.
- →Full-year CAPEX guidance remains around Rs. 500 crores despite higher Q1 spend.
- →The company emphasizes that registration activities are full of uncertainties with timelines and costs unpredictable.
- →Investments in new product registrations are ongoing and crucial for long-term growth and margin improvement.
- →The amortization related to these new registrations impacts quarterly results but is expected to stabilize on an annualized basis.
- →No specific mention of strategic acquisitions or expansions beyond registration investments.
💰 Fundraising & Capital Structure
No information- →There is no indication in the document of any current or planned fundraising through debt or equity.
- →The company remains debt-free as of June 30, 2026.
- →The company has a strong cash, bank, and liquid investment position of Rs. 767 crores as of June 30, 2026, up from Rs. 702 crores as of March 31, 2026.
- →The management has not mentioned any plans to raise capital through debt or equity.
- →Capex guidance remains around Rs. 500 crores for the year, with no upward revision despite higher spending in Q1.
- →The company appears focused on organic growth and sustained investment in product registrations without external fundraising.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
What Sharda Cropchem's management said in earlier quarters
Others in Fertilizers & Agrochemicals this season
- GSP Crop Science (Q1 FY27)
Capacity utilization indicates room for growth: 70-75% for technical and 25-30% for formulations. Key concall takeaways from GSP Crop Science Ltd's Q1 FY27…
- Rallis India (Q1 FY27)
. Key concall takeaways from Rallis India's Q1 FY27 earnings call — and how it ranks against sector peers.
- Coromandel Inter (Q1 FY27)
Specialty Nutrient business growing consistently at 25%-30% with high EBITDA margins (~20%). Key concall takeaways from Coromandel Inter's Q1 FY27 earnings…
- Meghmani Organi. (Q1 FY27)
Capacity utilization likely to stay around 40-50%. Key concall takeaways from Meghmani Organics Ltd's Q1 FY27 earnings call — and how it ranks against sector…
Frequently Asked Questions
What were Sharda Cropchem Q1 FY27 results?
The company maintains FY27 revenue growth guidance of 10%-15%. The company expects sustained revenue growth of 10%-15% for FY27.
What is Sharda Cropchem share price analysis?
Sharda Cropchem currently shows a below-average growth signal. The stock trades at a P/E of 11.0 with a market cap of ₹6,865 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sharda Cropchem planning capital expenditure?
Sharda Cropchem continues to invest significantly in intangible CAPEX, mainly product registrations, with annual investment around Rs.
Keep Sharda Cropchem on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.